Abstract
Obesity is a major health problem and as a result, it is reasonable to consider pharmacological approaches alongside approaches involving diet, physical activity and lifestyle change. The currently available drugs, sibutramine and orlistat, result in modest, clinically worthwhile weight loss, with demonstrable improvements in co-morbidity, but do not meet the often unrealistic expectations of patients or health care professionals managing obese patients. There is insufficient data on efficacy or safety of other agents to support their use. Many new pharmacological approaches are under investigation. These include gut hormones, such a peptide YY (3-36) and cholecystokinin that normally signal satiety, and centrally acting agents such a serotonin agonists, the anticonvulsants topiramate and zonisamide, cannabinoid receptor antagonists and drugs that act on other peptide neurotransmitter systems such as NPY and the melanocortins. Given the multiple pathways that influence energy balance, it is likely that therapies targeting more than one control system may be required in the future to meet the expectations and needs of patients needing to lose weight for medical reasons.
Keywords: anti-obesity drugs, obesity, sibutramine, anticonvulsants topiramate, cannabinoid receptor antagonists
Current Drug Targets
Title: Clinical Evaluation of Anti-Obesity Drugs
Volume: 5 Issue: 3
Author(s): John Wilding
Affiliation:
Keywords: anti-obesity drugs, obesity, sibutramine, anticonvulsants topiramate, cannabinoid receptor antagonists
Abstract: Obesity is a major health problem and as a result, it is reasonable to consider pharmacological approaches alongside approaches involving diet, physical activity and lifestyle change. The currently available drugs, sibutramine and orlistat, result in modest, clinically worthwhile weight loss, with demonstrable improvements in co-morbidity, but do not meet the often unrealistic expectations of patients or health care professionals managing obese patients. There is insufficient data on efficacy or safety of other agents to support their use. Many new pharmacological approaches are under investigation. These include gut hormones, such a peptide YY (3-36) and cholecystokinin that normally signal satiety, and centrally acting agents such a serotonin agonists, the anticonvulsants topiramate and zonisamide, cannabinoid receptor antagonists and drugs that act on other peptide neurotransmitter systems such as NPY and the melanocortins. Given the multiple pathways that influence energy balance, it is likely that therapies targeting more than one control system may be required in the future to meet the expectations and needs of patients needing to lose weight for medical reasons.
Export Options
About this article
Cite this article as:
Wilding John, Clinical Evaluation of Anti-Obesity Drugs, Current Drug Targets 2004; 5 (3) . https://dx.doi.org/10.2174/1389450043490479
DOI https://dx.doi.org/10.2174/1389450043490479 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Endothelin in Uteroplacental Circulation and Fetal Vascular Function
Current Vascular Pharmacology Editorial [Hot topic:Vascular Protective Effects of Ezetimibe: Seeking New Therapeutic Possibilities of Ezetimibe in Vascular Disease (Guest Editor: Minako Yamaoka-Tojo)]
Current Vascular Pharmacology Editorial from Guest Editor [Hot Topic:Vitamin D and Respiratory Health (Guest Editor: Adrian R. Martineau)]
Current Respiratory Medicine Reviews Disruption of Circadian Rhythms in Critical Illness - A Role of Hyperoxia-Induced Lung Injury
Current Pharmaceutical Design From the Oxygen to the Organ Protection: Erythropoietin as Protagonist in Internal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Dietary Regulation of Glucose Metabolism in Metabolic Syndrome
Current Vascular Pharmacology Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design Statins and Ischaemia Reperfusion Injury: A Molecular Biological Review
Current Vascular Pharmacology The Therapeutic Potential of Induced Pluripotent Stem Cells After Stroke: Evidence from Rodent Models
Current Stem Cell Research & Therapy Triggers and Anatomical Substrates in the Genesis and Perpetuation of Atrial Fibrillation
Current Cardiology Reviews Optimized Turmeric Extracts have Potent Anti-Amyloidogenic Effects
Current Alzheimer Research Epidemiology and Pathophysiology of Chronic Cough
Current Respiratory Medicine Reviews Metabolic and Cardiovascular Complications of Highly Active Antiretroviral Therapy for HIV Infection
Current HIV Research Estriol Inhibits Dermcidin Isoform-2 Induced Inflammatory Cytokine Expression Via Nitric Oxide Synthesis in Human Neutrophil
Current Molecular Medicine Palliative Combined Percutaneous Balloon Aortic Valvuloplasty and Unprotected Left Main Stenting in End Stage Renal Disease
Current Cardiology Reviews Smoking and Weight
Current Respiratory Medicine Reviews Vasopressin in Health and Disease with a Focus on Affective Disorders
Central Nervous System Agents in Medicinal Chemistry Estrogen Receptors as Targets for Drug Development for Breast Cancer, Osteoporosis and Cardiovascular Diseases
Current Cancer Drug Targets Endothelial Cells Facilitate Cell-Based Cardiac Repair: Progress and Challenge
Current Stem Cell Research & Therapy Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery